The exploration of ALDH3A1’s pathogenic mechanism in NSCLC has contributed to the discovery of effective therapeutic drugs targeting ALDH3A1 and combatting drug resistance, providing new clues for the identification of new precision therapeutic targets. The gene discussed is ALDH3A1; the disease is non-small cell lung carcinoma.